Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,665 across all filing types
Latest filing 2018-03-14 Board/Management Inform…
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Company Secretary Appointment/Resignation 2 pages 386.0KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement regarding the resignation and appointment of the Company Secretary at Admedus Limited. It details personnel changes in the company's leadership team, specifically the Company Secretary role. There is no financial data, report, or regulatory filing referenced beyond this management change. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2018-03-14 English
Admedus update on TAVR project 3 pages 408.7KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Admedus Limited about a developmental milestone achieved in their Transcatheter Aortic Valve Replacement (TAVR) project. It discusses passing a durability test and ongoing research and development efforts. There are no financial statements, no mention of quarterly or annual results, no voting results, no management changes, no legal proceedings, no financing updates, and no regulatory certifications. The document is a corporate announcement about a product development milestone, which fits best under general regulatory announcements or company updates that do not fit other specific categories. It is not a report, transcript, or financial filing. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is 5892 characters, which is sufficient for a substantive announcement but does not contain financial data or detailed report content.
2018-03-11 English
Admedus contracts with US Group Purchasing Organisation 2 pages 360.4KB
Capital/Financing Update Classification · 90% confidence The document is an ASX announcement dated 09.03.18 from Admedus Limited regarding a new purchasing agreement with a Group Purchasing Organisation in the US. It discusses business development and market expansion but does not contain financial statements, detailed financial analysis, or regulatory certifications. The document is relatively short (3361 characters) and reads as a corporate announcement about a commercial agreement rather than a financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is not a report publication announcement since it does not mention any report being published or attached. The content is best classified as a Capital/Financing Update (CAP) because it relates to a significant commercial agreement that impacts the company's market and revenue potential, which aligns with updates on company financing activities or capital structure changes.
2018-03-08 English
CANADA REGULATORY APPROVAL GRANTED - CARDIOCEL 3D, VASCUCEL 2 pages 413.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Admedus Limited regarding regulatory approval granted in Canada for specific medical products. It is a brief announcement about a regulatory milestone and market expansion, without any financial statements, detailed financial analysis, or management discussion. The document length is 3809 characters, which is relatively short and typical for a regulatory announcement. There is no indication that this is a full report, earnings release, or management discussion. It is not a certification or officer attestation. The content fits best with a Regulatory Filings (RNS) category, which is the fallback for general regulatory announcements that do not fit other specific categories.
2018-03-06 English
Appendix 4E & 31 December 2017 Financial Report 72 pages 823.9KB
Interim / Quarterly Report Classification · 95% confidence The document is a detailed financial report from Admedus Limited for the six-month period ended 31 December 2017. It includes comprehensive financial data such as revenue, profit margins, operating costs, cash flows, and detailed notes on business activities and results. The document also contains a Directors' Report, Auditor's Independence Declaration, Consolidated Statements of Profit or Loss, Financial Position, Cash Flows, and an Independent Auditor's Report. The presence of these detailed financial statements and the length of the document (15,000 characters) indicate this is a full financial report rather than a brief announcement or summary. The document explicitly states it is a "Financial Report for the Period Ended 31 December 2017" and includes audited financial statements. Therefore, this document fits the definition of an Interim / Quarterly Report (IR) as it covers a period shorter than a full fiscal year and contains substantive financial data and analysis. It is not an Annual Report (10-K) because it covers only six months, not a full fiscal year. It is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA) because it contains the full report, not just an announcement or certification. Hence, the correct classification is Interim / Quarterly Report (IR). H2 2017
2018-02-27 English
Company Secretary Appointment/Resignation, Change of Address 2 pages 391.4KB
Board/Management Information Classification · 95% confidence The document is an ASX announcement dated 27 February 2018 regarding the resignation and appointment of the Company Secretary and a change of the registered office address for Admedus Limited. It contains no financial data, no discussion of financial results, no voting results, no legal proceedings, no capital changes, and no other report content. It is a corporate governance update about management changes and office location. This fits the category of Board/Management Information (MANG). The document length is 3069 characters, which is short and consistent with an announcement rather than a full report. Therefore, the classification is MANG with high confidence.
2018-02-26 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.